Preparation and immunogenicity of an inactivated hepatitis A vaccine.
A hepatitis A vaccine was prepared by formaldehyde inactivation of purified hepatitis A virus (HAV) LSH/S strain grown on human diploid MRC-5 cells. The vaccine was devoid of residual infectivity in vitro and failed to induce in marmoset monkeys any pathological features or variations of haematological and clinical chemistry values. Infectious HAV particles were not detected in faeces and sera of the vaccinated primates by ELISA or after passages in MRC-5 cells. The immunogenicity of the vaccine was evaluated by injecting guinea-pigs with 0.8, 0.2 or 0.05 micrograms of HAV antigen adsorbed onto 0.5 and 1 mg of Al (OH)3 or 0.3 mg of AlPO4. The antibody response, measured by a competitive radioimmunoassay, was dose- and adjuvant-dependent. One injection of 0.2 micrograms of AlPO4-adsorbed HAV antigen induced seroconversion in 100% of animals and high levels of specific and neutralizing serum antibodies. A further increase of antibody titres was observed after the second and third inoculations. These results show that this vaccine formulation is safe and immunogenic in animal models, and suggest that it should be evaluated further by human clinical studies.
IRIS, Siena, Italy.
V
V
Pellegrini
N
N
Fineschi
G
G
Matteucci
I
I
Marsili
L
L
Nencioni
M
M
Puddu
H
H
Garelick
A J
AJ
Zuckerman
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000535:Aluminum / Q000008:administration & dosage; D017607:Aluminum Compounds; D000536:Aluminum Hydroxide / Q000008:administration & dosage; D000818:Animals; D002144:Callithrix; D002460:Cell Line; D006168:Guinea Pigs; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies / Q000097:blood; D006507:Hepatovirus / Q000254:growth & development / Q000276:immunology; D006801:Humans; D010710:Phosphates / Q000008:administration & dosage; D015164:Vaccines, Inactivated / Q000302:isolation & purification / Q000494:pharmacology / Q000633:toxicity; D014761:Viral Hepatitis Vaccines / Q000302:isolation & purification* / Q000494:pharmacology / Q000633:toxicity
D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D010710:Phosphates; D015164:Vaccines, Inactivated; D014761:Viral Hepatitis Vaccines; D000536:Aluminum Hydroxide; D000535:Aluminum; C012714:aluminum phosphate